Company Overview and News

0
Medical Cannabis Payment Solutions’ SpeedyGrow Featured on KREX News Story

2018-06-07 globenewswire
LAS VEGAS, June 07, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced that its subsidiary, SpeedyGrow, was featured on KREX’s news story about CBD and hemp. KREX is the CBS-affiliated television station in Grand Junction, Colorado.
REFG

20
Cannabis Sativa Inc. Makes Huge Losses On Little Revenue. What Is Going On Here?

2018-05-30 seekingalpha
If you are into the marijuana sector hype, it might be tempting to scoop up one of the smaller players exposed to different use cases for legal cannabis. The company has a portfolio of these, which I'll quickly present later. However, I strongly feel there are too many warning signs concerning Cannabis Sativa Inc. (OTCQB:CBDS) for a prudent investor to take a stake.
TWMJF ACB WEED ACBFF REFG CGC CBDS

0
Medical Cannabis Payment Solutions Announces Acquisition of 40 Acres to Grow Hemp

2018-05-29 globenewswire
LAS VEGAS, May 29, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that it has acquired 40 acres of agricultural land to cultivate hemp as part of Utah’s recently passed law, H.B. 302. The company will seek a license to grow hemp as part of the state’s Department of Agriculture and Food licensing program.
REFG

0
Medical Cannabis Payment Solutions Announces Acquisition, State License

2018-05-17 globenewswire
LAS VEGAS, May 17, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that it has acquired SpeedyGrow, a Wyoming corporation with licenses to grow and process hemp in the state of Colorado. The company extracts full spectrum CBD.
REFG

0
Medical Cannabis Payment Solutions to Offer Bank Accounts for State Licensed Medical Marijuana Establishments

2018-04-18 globenewswire
LAS VEGAS, April 18, 2018 (GLOBE NEWSWIRE) -- via NetworkWire --Medical Cannabis Payment Solutions (OTC:REFG), a leader in technological solutions for the medical cannabis industry, announced today the company will begin offering bank accounts to qualified and licensed medical marijuana establishments. The company’s website, www.take.green, will be updated shortly to allow online applications for banking services.
REFG

0
Medical Cannabis Payment Solutions’ (REFG) ‘Green’ Sees Dramatic Increase in Applications Since March 16 Launch on Take.green Website

2018-04-04 globenewswire
LAS VEGAS, April 04, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Medical Cannabis Payment Solutions (REFG), a Nevada corporation specializing in state-of-the-art financial services structured to serve the medical cannabis and banking industries, announced today that state-licensed marijuana establishments may sign up via its website for its banking and financial processing system. The company, which has been working with targeted establishments, has now made its services available to the entire industry.
REFG

0
Medical Cannabis Payment Solutions Fully Launches Payment System, Establishments May Now Enroll

2018-03-16 globenewswire
LAS VEGAS, March 16, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- Medical Cannabis Payment Solutions (OTC:REFG), a Nevada corporation that specializes in state-of-the-art financial services structured to serve the medical cannabis and banking industry, announced today that state licensed marijuana establishments may sign up via its website for its banking and financial processing system. The company, which has been working with targeted establishments, has now made its services available to the entire industry.
REFG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...